Clinical Trials
26 trialsEZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Takeda
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Therapeutic Advances in Childhood Leukemia Consortium
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Therapeutic Advances in Childhood Leukemia Consortium
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
University of Texas Southwestern Medical Center
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Therapeutic Advances in Childhood Leukemia Consortium
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Masonic Cancer Center, University of Minnesota
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
St. Jude Children's Research Hospital
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Fred Hutchinson Cancer Center
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Northside Hospital, Inc.
Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
Children's Hospital of Philadelphia
Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer
University of California, San Francisco
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
H. Lee Moffitt Cancer Center and Research Institute
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
OHSU Knight Cancer Institute
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
M.D. Anderson Cancer Center
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital